NewPro Closes Tens of Millions of RMB in Pre-A Funding Led by Dalton Venture and SSCI Leading Fund, Achieves FDA Self-GRAS Certification for Self-Developed Lactoferrin | Dalton Venture News
Recently, **NewPro Bioworks (Shanghai Xinyicui Biotechnology Co., Ltd.) announced the completion of a Pre-A funding round worth tens of millions of RMB**. This round was jointly led by **SSCI Leading Fund and Aochuang Pioneer Fund — the latter established by Dalton Venture in partnership with listed industry player OPM Biosciences, making it the first bio-manufacturing industry CVC fund in the Yangtze River Delta region**. Meanwhile, the company's self-developed precision-fermented lactoferrin product
Background
Recently, NewPro Bioworks (Shanghai Xinyicui Biotechnology Co.) announced the completion of a tens-of-millions-of-yuan Pre-A funding round. The round was co-led by SSCI Leading Fund and Aochuang Pioneer Fund, with the latter established by Dalton Venture together with listed industrial partner OPM Biosciences — the first bio-manufacturing industry CVC fund in the Yangtze River Delta region. At the same time, the company's self-developed precision-fermented lactoferrin product officially received U.S. FDA Self-GRAS (Generally Recognized As Safe) certification, marking a critical breakthrough in international market access for its core product.
Proceeds from this round will be directed toward three priorities: first, accelerating the regulatory application process for lactoferrin as a new food ingredient in China; second, deepening overseas market expansion and driving commercialization of the FDA Self-GRAS-certified product in international markets; and third, advancing scaled production capacity for functional food proteins.
This investment represents Aochuang Pioneer Fund's key strategic move in the synthetic biology food innovation space, with the fund aiming to aggregate industrial innovation resources and drive breakthroughs in bio-manufacturing technologies while nurturing innovative enterprises.
Image provided by the company
NewPro Bioworks is a bio-manufacturing company deeply rooted in synthetic biology. Leveraging its advanced industrial chassis engineering technology system FlexBaseTM and intelligent precision fermentation process NeuroBrewTM, the company focuses on bio-manufacturing functional proteins that are scarce in nature.
Through its self-developed FlexBaseTM industrial chassis engineering system, the company achieves standardized plug-and-play bio-components for industrial microbial chassis, dry-wet integrated high-throughput screening, and dedicated cellular compartmentalization for functional remodeling. In the expression and secretion of its core product lactoferrin, for example, FlexBaseTM resolves the challenges of complex protein modifications — particularly deep simulation of glycosylation — ensuring that precision-fermented recombinant proteins are highly consistent with their natural counterparts. Powered by the intelligent precision fermentation process NeuroBrewTM, NewPro Bioworks has accumulated thousands of batches of fermentation data at pilot scale, forming AI-specific data models that enable intelligent fermentation control and process optimization at pilot and production scales based on dedicated models. This process technology ensures efficient, stable, and low-cost production of lactoferrin and other functional ingredients.
Meanwhile, building on a solid foundation for lactoferrin commercialization, the company continues to develop multiple high-value functional food protein pipelines including osteopontin and ovalbumin. It is committed to leveraging advanced bio-manufacturing technology to create safe, high-quality, and sustainable innovative food ingredient solutions, driving the industrial adoption of synthetic biology in consumer applications.
Regarding this investment, Dalton Venture stated: We are honored to participate in this funding round. High-value functional protein ingredients produced through bio-manufacturing represent a core sector with both technological moats and market potential. With its self-developed chassis engineering technology platform, NewPro has taken the lead in achieving pilot-scale production of food-grade recombinant lactoferrin and securing FDA Self-GRAS certification, placing its commercialization progress in the first tier domestically among peers. Aochuang Pioneer Fund will fully leverage its CVC industrial synergy advantages, connecting upstream and downstream industrial resources to comprehensively empower the company's capacity building and global market expansion, helping it grow into a benchmark enterprise in China's bio-manufacturing sector.
ID: daltonventure
Long press to follow
Recommended Reading
